PRODUCTS & SERVICES
The excellent work of MultiplexDX's scientific team which identifies and quantifies new RNA biomarkers for cancer and other human diseases highlights the fact that we became an important part of a consortium of Czech and Slovak institutions that successfully won a prestigious 5 million project funded by the program Horizon Europe. As a result, the new Czech-Slovak center of excellence will be developed, validated, and implemented into a modern clinic and innovative diagnosis of Alzheimer's disease.
More than 55 million people worldwide suffer from dementia. Alzheimer’s disease is the leading cause of this fatal disorder without effective disease-modifying therapy. Early diagnosis and lifestyle can significantly reduce the costs of care and treatment. There is no conceptual plan for implementing modern diagnostics methods in the clinical practice in Czechia and Slovakia. The interaction between universities and the private sector which are developing molecular diagnostic tools is fragmented and lacking.
The project will interlink two ecosystems in Brno and Bratislava region, embracing the innovation-driving actors - excellent scientific teams from Masaryk University and Slovak Academy of Sciences, collaborating with top biotech companies – MultiplexDX International, Geneton and BioVendor. Societal actors will be represented by organizations such as Slovak Alzheimer Society and Czech Alzheimer Society, Memory Center, and Czech Brain Aging Study. The regional government will be involved via the Ministry of Health of the Slovak Republic and JIC – business with a purpose.
The result of this project should be a new, modern and revolutionary diagnosis of Alzheimer's disease transferred into clinical practice in the Czech and Slovak Republics, which will enable timely intervention and monitoring of the progression of this neurodegenerative disease in patients. The project will contribute to spreading awareness about Alzheimer's disease in the public, as well as to the creation of national plans to fight this disease both in Slovakia and Czech Republic.
The project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101087124
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.